Picrasidine S Induces cGAS-Mediated Cellular Immune Response as a Novel Vaccine Adjuvant.

Autor: Ding X; Institute for Immunology and School of Basic Medical Sciences, and Beijing Key Laboratory for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China., Sun M; Institute for Immunology and School of Basic Medical Sciences, and Beijing Key Laboratory for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China., Guo F; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, China., Qian X; Institute for Immunology and School of Basic Medical Sciences, and Beijing Key Laboratory for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China., Yuan H; Institute for Immunology and School of Basic Medical Sciences, and Beijing Key Laboratory for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China., Lou W; Institute for Immunology and School of Basic Medical Sciences, and Beijing Key Laboratory for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China., Wang Q; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, China., Lei X; Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, China.; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.; Institute of Cancer Research, Shen Zhen Bay Laboratory, Shen Zhen, 518107, China., Zeng W; Institute for Immunology and School of Basic Medical Sciences, and Beijing Key Laboratory for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China.; SXMU-Tsinghua Collaborative Innovation Center for Frontier Medicine, Taiyuan, 030001, China.; Tsinghua-Peking Center for Life Sciences, Beijing, 100084, China.
Jazyk: angličtina
Zdroj: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2024 Aug; Vol. 11 (32), pp. e2310108. Date of Electronic Publication: 2024 Jun 20.
DOI: 10.1002/advs.202310108
Abstrakt: New adjuvants that trigger cellular immune responses are urgently needed for the effective development of cancer and virus vaccines. Motivated by recent discoveries that show activation of type I interferon (IFN-I) signaling boosts T cell immunity, this study proposes that targeting this pathway can be a strategic approach to identify novel vaccine adjuvants. Consequently, a comprehensive chemical screening of 6,800 small molecules is performed, which results in the discovery of the natural compound picrasidine S (PS) as an IFN-I inducer. Further analysis reveals that PS acts as a powerful adjuvant, significantly enhancing both humoral and cellular immune responses. At the molecular level, PS initiates the activation of the cGAS-IFN-I pathway, leading to an enhanced T cell response. PS vaccination notably increases the population of CD8+ central memory (T CM )-like cells and boosts the CD8+ T cell-mediated anti-tumor immune response. Thus, this study identifies PS as a promising candidate for developing vaccine adjuvants in cancer prevention.
(© 2024 The Author(s). Advanced Science published by Wiley‐VCH GmbH.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje